Clara Albanese

1.0k total citations
19 papers, 459 citations indexed

About

Clara Albanese is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Clara Albanese has authored 19 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Clara Albanese's work include Cancer-related Molecular Pathways (5 papers), HER2/EGFR in Cancer Research (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Clara Albanese is often cited by papers focused on Cancer-related Molecular Pathways (5 papers), HER2/EGFR in Cancer Research (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Clara Albanese collaborates with scholars based in Italy, United States and New Zealand. Clara Albanese's co-authors include Deborah H. Brotherton, Corrado Santocanale, Pierluigi Tenca, Alessia Montagnoli, Francesco Sola, Daniela Carpani, Sonia Rainoldi, Rachele Alzani, Enrico Pesenti and Fabio Gasparri and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Immunology and PLoS ONE.

In The Last Decade

Clara Albanese

19 papers receiving 453 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Clara Albanese Italy 12 292 232 93 57 52 19 459
Laura Bazley United Kingdom 3 253 0.9× 254 1.1× 73 0.8× 78 1.4× 19 0.4× 4 436
Isabelle Lelong-Rebel France 12 255 0.9× 173 0.7× 77 0.8× 117 2.1× 20 0.4× 19 492
Danny Rickwood Australia 11 427 1.5× 208 0.9× 77 0.8× 122 2.1× 13 0.3× 13 598
Michael F. Emmons United States 15 456 1.6× 234 1.0× 60 0.6× 53 0.9× 16 0.3× 24 676
Aleksandra Simiczyjew Poland 16 295 1.0× 213 0.9× 115 1.2× 101 1.8× 21 0.4× 29 555
Irina Primac Belgium 10 338 1.2× 260 1.1× 79 0.8× 229 4.0× 52 1.0× 12 669
Marina Chan United States 10 331 1.1× 200 0.9× 86 0.9× 77 1.4× 19 0.4× 16 534
Stacy M. Plum United States 8 200 0.7× 104 0.4× 78 0.8× 76 1.3× 19 0.4× 10 348
Divyamani Srinivasan United States 6 252 0.9× 109 0.5× 39 0.4× 28 0.5× 43 0.8× 7 390
Karin H. Yohem United States 7 263 0.9× 128 0.6× 121 1.3× 70 1.2× 27 0.5× 9 448

Countries citing papers authored by Clara Albanese

Since Specialization
Citations

This map shows the geographic impact of Clara Albanese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clara Albanese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clara Albanese more than expected).

Fields of papers citing papers by Clara Albanese

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clara Albanese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clara Albanese. The network helps show where Clara Albanese may publish in the future.

Co-authorship network of co-authors of Clara Albanese

This figure shows the co-authorship network connecting the top 25 collaborators of Clara Albanese. A scholar is included among the top collaborators of Clara Albanese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clara Albanese. Clara Albanese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Valsasina, Barbara, Paolo Orsini, Michele Caruso, et al.. (2023). Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies. Molecular Cancer Therapeutics. 22(12). 1465–1478. 4 indexed citations
2.
Golay, Josée, Rachele Alzani, Clara Albanese, et al.. (2018). Cord blood–derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors. Cytotherapy. 20(8). 1077–1088. 14 indexed citations
3.
Angerani, Simona, Clelia Giannini, Daniela Arosio, et al.. (2017). Tumor Targeting with an isoDGR–Drug Conjugate. Chemistry - A European Journal. 23(33). 7910–7914. 17 indexed citations
4.
Caruso, Michele, Laura Belvisi, Daniela Arosio, et al.. (2017). Targeting Integrin α V β 3 with Theranostic RGD‐Camptothecin Conjugates Bearing a Disulfide Linker: Biological Evaluation Reveals a Complex Scenario. ChemistrySelect. 2(17). 4759–4766. 14 indexed citations
5.
Corso, Alberto Dal, Michele Caruso, Laura Belvisi, et al.. (2015). Synthesis and Biological Evaluation of RGD Peptidomimetic–Paclitaxel Conjugates Bearing Lysosomally Cleavable Linkers. Chemistry - A European Journal. 21(18). 6921–6929. 50 indexed citations
6.
Banfi, Patrizia, Fabio Gasparri, R. M. Borzilleri, et al.. (2014). Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers. Experimental Cell Research. 332(2). 267–277. 27 indexed citations
7.
Valsasina, Barbara, Fabio Gasparri, Italo Beria, et al.. (2014). Abstract 822: Thienoindoles, a novel class of DNA minor groove alkylating agents highly suited for the generation of novel antibody drug conjugates (ADCs). Cancer Research. 74(19_Supplement). 822–822. 1 indexed citations
8.
Golay, Josée, Gianmaria Borleri, Rut Valgardsdottir, et al.. (2014). A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy. The Journal of Immunology. 193(9). 4739–4747. 24 indexed citations
9.
Calogero, Francesco, Gaetano Speciale, Michael S. Christodoulou, et al.. (2013). 9‐Fluorenone‐2‐Carboxylic Acid as a Scaffold for Tubulin Interacting Compounds. ChemPlusChem. 78(7). 663–669. 8 indexed citations
10.
Golay, Josée, Clara Albanese, Roberta Ceruti, et al.. (2013). The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia. PLoS ONE. 8(3). e58424–e58424. 30 indexed citations
11.
Albanese, Clara, Rachele Alzani, Nadia Amboldi, et al.. (2013). Anti‐tumour efficacy on glioma models of PHA‐848125, a multi‐kinase inhibitor able to cross the blood–brain barrier. British Journal of Pharmacology. 169(1). 156–166. 18 indexed citations
12.
Albanese, Clara, Rachele Alzani, Nadia Amboldi, et al.. (2010). Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy. Molecular Cancer Therapeutics. 9(8). 2243–2254. 51 indexed citations
13.
Alzani, Rachele, Olga Pedrini, Clara Albanese, et al.. (2010). Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. Experimental Hematology. 38(4). 259–269.e2. 11 indexed citations
14.
Colotta, Francesco, Jürgen Moll, Barbara Valsasina, et al.. (2010). Abstract DD01-01: NMS-1116354: More than an inhibitor of Cdc 7 kinase in S-phase. Cancer Research. 70(8_Supplement). DD01–1. 1 indexed citations
15.
Alzani, Rachele, Clara Albanese, Giuseppe Locatelli, et al.. (2008). 294 POSTER Biological characterization of the dual CDK2/TRKA inhibitor PHA-848125. European Journal of Cancer Supplements. 6(12). 94–95. 1 indexed citations
16.
Tenca, Pierluigi, Deborah H. Brotherton, Alessia Montagnoli, et al.. (2006). Cdc7 Is an Active Kinase in Human Cancer Cells Undergoing Replication Stress. Journal of Biological Chemistry. 282(1). 208–215. 62 indexed citations
17.
Montagnoli, Alessia, Pierluigi Tenca, Francesco Sola, et al.. (2004). Cdc7 Inhibition Reveals a p53-Dependent Replication Checkpoint That Is Defective in Cancer Cells. Cancer Research. 64(19). 7110–7116. 107 indexed citations
18.
Mercurio, Ciro, Wilma Pastori, Rachele Alzani, et al.. (2004). In vitro and in vivo characterization of the CDK2 inhibitor PHA-533533. 64. 190–190. 2 indexed citations
19.
Geroni, Cristina, Marina Ripamonti, Claudio Arrigoni, et al.. (2001). Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent.. PubMed. 61(5). 1983–90. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Bazley Breakdown of academic impact, for papers by Isabelle Lelong-Rebel Breakdown of academic impact, for papers by Danny Rickwood Breakdown of academic impact, for papers by Michael F. Emmons Breakdown of academic impact, for papers by Aleksandra Simiczyjew Breakdown of academic impact, for papers by Irina Primac Breakdown of academic impact, for papers by Marina Chan Breakdown of academic impact, for papers by Stacy M. Plum Breakdown of academic impact, for papers by Divyamani Srinivasan Breakdown of academic impact, for papers by Karin H. Yohem
Rankless by CCL
2026